Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04818853 · ClinicalTrials.gov registry record
COVID-19 Associated Pulmonary Aspergillosis (CAPA) and Other Invasive Fungal Infections (IFI)
A clinical trial, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- 219
- Enrollment target
NCT04818853 is a clinical trial that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 219 participants.
The verdict
NCT04818853 has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- 219 participants
- Enrollment target
Study Summary
The purpose of this study is to identify the number of individuals with severe CoVID who require ventilator support and who develop serious fungal infections. The study is an observational study, meaning that we are not providing any intervention that does not involve usual standard of care. Our chief goal is to find evidence of fungal infection by using traditional, approved methods of diagnosis, but by applying these methods in the same way and frequency among all study participants. We will be looking especially for evidence of a fungal infection known as Aspergillus, which can causes a serious lung infection called invasive aspergillosis (IA).
Interventions
- OTHER Observation to monitor patients for these infections
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 219 participants |
| Start Date | 2021-03-09 |
| Est. Completion | 2023-01-13 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04818853
The ClinicalTrials.gov registry entry for NCT04818853 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 219 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Observation to monitor patients for these infections is the first listed.
NCT04818853 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04818853 about?
NCT04818853 is a clinical study titled "COVID-19 Associated Pulmonary Aspergillosis (CAPA) and Other Invasive Fungal Infections (IFI)". The purpose of this study is to identify the number of individuals with severe CoVID who require ventilator support and who develop serious fungal infections. The study is an observational study, meaning that we are not providing any intervention that does not involve usual standard of care. Our chi...
What is the current status of trial NCT04818853?
This trial is currently completed. The enrollment target is 219 participants. The study started on 2021-03-09. Estimated completion is 2023-01-13.
What interventions are being tested in trial NCT04818853?
The interventions under investigation include: Observation to monitor patients for these infections (OTHER).
Who is sponsoring clinical trial NCT04818853?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.